Reuters logo
Merck to buy NovaCardia to expand heart drug pipeline
July 25, 2007 / 12:45 PM / 10 years ago

Merck to buy NovaCardia to expand heart drug pipeline

July 25 (Reuters) - Merck & Co. Inc. (MRK.N) said it agreed to acquire privately held NovaCardia in a deal worth $350 million to boost its clinical pipeline for cardiovascular drug candidates.

NovaCardia focuses on cardiovascular diseases and the acquisition will give Merck access to NovaCardia’s lead experimental drug, KW-3902, for acute congestive heart failure which is in the last stage of trials. (Reporting by Jennifer Robin Raj in Bangalore)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below